- Home
- MGIC vs REVBW Comparison
MGIC vs REVBW Comparison
Compare MGIC & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- REVBW
- Stock Information
- Founded
- MGIC 1983
- REVBW N/A
- Country
- MGIC Israel
- REVBW United States
- Employees
- MGIC N/A
- REVBW 9
- Industry
- MGIC Computer Software: Prepackaged Software
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- REVBW Health Care
- Exchange
- MGIC Nasdaq
- REVBW Nasdaq
- Market Cap
- MGIC N/A
- REVBW N/A
- IPO Year
- MGIC 1991
- REVBW 2020
- Fundamental
- Price
- MGIC $13.72
- REVBW $0.02
- Analyst Decision
- MGIC Buy
- REVBW
- Analyst Count
- MGIC 2
- REVBW 0
- Target Price
- MGIC $16.00
- REVBW N/A
- AVG Volume (30 Days)
- MGIC 98.9K
- REVBW N/A
- Earning Date
- MGIC 03-11-2025
- REVBW N/A
- Dividend Yield
- MGIC 3.21%
- REVBW N/A
- EPS Growth
- MGIC N/A
- REVBW N/A
- EPS
- MGIC 0.75
- REVBW N/A
- Revenue
- MGIC $552,520,000.00
- REVBW N/A
- Revenue This Year
- MGIC $4.41
- REVBW N/A
- Revenue Next Year
- MGIC $4.91
- REVBW N/A
- P/E Ratio
- MGIC $18.65
- REVBW N/A
- Revenue Growth
- MGIC N/A
- REVBW N/A
- 52 Week Low
- MGIC $9.51
- REVBW N/A
- 52 Week High
- MGIC $14.04
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- MGIC 63.61
- REVBW N/A
- Support Level
- MGIC $11.65
- REVBW N/A
- Resistance Level
- MGIC $14.04
- REVBW N/A
- Average True Range (ATR)
- MGIC 0.40
- REVBW 0.00
- MACD
- MGIC 0.15
- REVBW 0.00
- Stochastic Oscillator
- MGIC 86.61
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).